 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
What's New in Treatment Information?Excerpts From Hotline Memos of March 2001
from the Information Department of Project Inform April 2001 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Valganciclovir Recommended for ApprovalThe Antiviral Drugs Advisory Committee to the Food and Drug Administration recommended that valganciclovir be approved for treating active CMV retinitis and maintenance therapy (to prevent relapse of CMV). Valganciclovir is an improved oral formulation of ganciclovir. Clinical studies show that valganciclovir is as effective as the intravenous (injection into the vein) form of the drug, which is commonly used to treat CMV disease. The dose used to treat CMV retinitis was 900mg twice a day for the first 21 days and then 900mg once a day for the next seven days. However, maintenance therapy usually requires the drug to be given lifelong. Valganciclovir is expected to be available in pharmacies in May 2001. In the meantime, an expanded access program is open for early access to the drug. Call Project Inform's Hotline toll-free at 1-800-822-7422 for a list of participating sites.
Back to the What's New? April 2001 Table of Contents.
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!  This article was provided by Project Inform. It is a part of the publication What's New. Visit Project Inform's website to find out more about their activities, publications and services.
|
|
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
